STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Acquires 3,620 Shares of Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 3,620 shares of the company’s stock in a transaction on Thursday, March 27th. The stock was bought at an average cost of $17.48 per share, with a total value of $63,277.60. Following the completion of the acquisition, the insider now owns 12,424,944 shares of the company’s stock, valued at $217,188,021.12. This represents a 0.03 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Tuesday, March 25th, Broadwood Partners, L.P. purchased 34,296 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.44 per share, for a total transaction of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. purchased 108,720 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.96 per share, with a total value of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. acquired 93,124 shares of STAAR Surgical stock. The stock was acquired at an average cost of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. purchased 249,503 shares of STAAR Surgical stock. The stock was acquired at an average cost of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The shares were bought at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The stock was bought at an average price of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The stock was purchased at an average cost of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The stock was purchased at an average cost of $21.50 per share, with a total value of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. purchased 21,155 shares of STAAR Surgical stock. The stock was acquired at an average price of $21.46 per share, with a total value of $453,986.30.

STAAR Surgical Price Performance

Shares of STAA stock opened at $17.79 on Friday. The firm has a fifty day moving average of $19.43 and a two-hundred day moving average of $25.23. The firm has a market cap of $877.49 million, a P/E ratio of -43.39 and a beta of 0.66. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $52.68.

Wall Street Analysts Forecast Growth

STAA has been the topic of several recent analyst reports. Stephens reiterated an “equal weight” rating and set a $17.00 target price on shares of STAAR Surgical in a research report on Tuesday, March 18th. Canaccord Genuity Group lowered their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a research report on Thursday, February 27th. William Blair lowered STAAR Surgical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 12th. Finally, Jefferies Financial Group cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $25.29.

Institutional Investors Weigh In On STAAR Surgical

Large investors have recently added to or reduced their stakes in the stock. Quarry LP acquired a new stake in shares of STAAR Surgical in the third quarter valued at approximately $50,000. Quest Partners LLC bought a new position in STAAR Surgical in the 3rd quarter worth approximately $128,000. KLP Kapitalforvaltning AS acquired a new stake in STAAR Surgical in the 4th quarter valued at approximately $180,000. Larson Financial Group LLC boosted its position in STAAR Surgical by 78.3% during the 3rd quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock worth $181,000 after acquiring an additional 2,135 shares during the period. Finally, Bridgefront Capital LLC increased its holdings in shares of STAAR Surgical by 27.2% during the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock valued at $262,000 after purchasing an additional 2,306 shares during the period. 96.70% of the stock is owned by institutional investors and hedge funds.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.